Skip to main content

Table 2 Studies comparing the impact of different antiemetics on HRQL

From: Impact of Nausea and Vomiting on Quality of Life in Cancer Patients During Chemotherapy

Author (study) [ref.]

Pts (no.)

Cancer (type)

Chemotherapy (emetogenicity)

Antiemetics

HRQL assessment (times)

Selection of pts

Soukop (DB) [17]

184

Breast

Moderately

DEX + OND vs DEX + MTC

RSCL (before and after 6 days)

187 pts eligible, 184 evaluated HRQL, 2 questions excluded (> 5% of pts no response)

Clavel (DB) [19]

252

Breast

Moderately (FAC, FEC)

OND vs ALI

FLIC, FLIE (before and after 4 days)

259 pts eligible, 252 evaluated HRQL with FLIC and 246 with FLIE

Crucitt (DB) [20]

113

Breast LNH

Moderately

OND vs PCP

FLIC, FLIE (before and after 4 days)

133 pts eligible, 113 evaluable for efficacy, 57 evaluated HRQL

Lofters (DB) [21]

696

various

Moderately

OND ± DEX vs DOL ± DEX

EORTC QLQ-C30 (before and after 4 and 8 days)

703 pts eligible, 696 evaluated HRQL

Pater (DB) [22]

402

various

Moderately

DEX + OND or DOL vs DEX (delayed emesis)

EORTC QLQ-C30 (before and after 4 and 8 days)

407 pts eligible, 402 evaluated HRQL

Garbe (DB) [23]

90

Melan

Highly (dacarbazine)

TROP 5 mg vs TROP 10 mg

Mood, food intake, QL scales (before and after CT)

n.s.

Barrenetxea (DB) [24]

182

Breast

Moderately (FAC, FEC)

OND for 3 days vs OND+MTC vs OND 1 dose

FLIC (before and for 5 days)

n.s.

Lebeau (DB) [25]

338

various

Highly (cisplatin)

OND+MP vs OND+MP+ MTP

FLIC, FLIE (before and after 4 days)

n.s.

Kobayashi (DB) [26]

141

various

Highly (cisplatin)

TROP vs PL (delayed emesis)

QOL-EVJ (before and daily for 30 days after)

146 pts enrolled, 141 eligible, 98 evaluated HRQL

Sorbe (R, O) [28]

259

various

Highly (cisplatin)

TROP vs MTC + DEX + LOR

23 items (before and after 7 days)

n.s.

Drechsler (R, O) [29]

191

various

Highly and Moderately

TROP vs TROP+DEX vs TROP+MTC

new scale (before and after CT)

n.s.

Torok (R, O) [30]

130

Ovary

Highly (cisplatin)

OND vs GRAN vs MTC

RSCL (before and daily for 5 days)

n.s.

Lachaine (O) [31]

52

Breast

Moderately

OND or MTC physician choice

EORTC QLQ-C30 (before and after 2 and 4 days)

58 pts eligible, 52 evaluated HRQL

  1. ALI: alizapride, CT: chemotherapy, DB = Double-blind, DEX: dexamethasone, GRAN: granisetron, HRQL: Health-related quality of life, Melan: melanoma, MTC: metoclopramide, MTP: metopimazine O: open, OND: ondansetron, PCP: prochlorperazine, PL: placebo, R: randomized, TROP: tropisetron, 5-HT3: 5-HT3 antagonist, n.s.: not specified